# Kyntra Bio clinical trials: 41 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 41 trials with Kyntra Bio as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Kyntra Bio: 41 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/kyntra-bio

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 41
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 41, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 23, 2026 | NCT07722988 | A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes... | Kyntra Bio | Phase 3 | Not yet recruiting | Myelodysplastic Syndromes | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07722988) |
| February 24, 2025 | NCT06842498 | A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Kyntra Bio | Phase 2 | Recruiting | Metastatic Castration-Resistant Prostate Cancer | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06842498) |
| March 29, 2022 | NCT05301517 | A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for... | Kyntra Bio | Phase 3 | Completed | Chemotherapy Induced Anemia | 159 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05301517) |
| November 17, 2020 | NCT04632940 | Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD | Kyntra Bio | Phase 3 | Terminated | Duchenne Muscular Dystrophy | 73 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04632940) |
| November 9, 2020 | NCT04621331 | Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD | Kyntra Bio | Phase 3 | Withdrawn | Anemia Associated With Chronic Kidney Disease | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04621331) |
| July 24, 2020 | NCT04484857 | Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants | Kyntra Bio | Phase 3 | Completed | Anemia Associated With End Stage Renal Disease | 283 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04484857) |
| June 16, 2020 | NCT04432298 | Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease | Kyntra Bio | Phase 2 | Terminated | COVID-19 | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04432298) |
| June 5, 2020 | NCT04419558 | Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Kyntra Bio | Phase 3 | Terminated | Idiopathic Pulmonary Fibrosis | 372 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04419558) |
| June 1, 2020 | NCT04410198 | Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in... | Kyntra Bio | Phase 3 | Completed | Anemia Associated With End Stage Renal Disease (ESRD) | 203 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04410198) |
| May 1, 2020 | NCT04371666 | Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD) | Kyntra Bio | Phase 3 | Terminated | Duchenne Muscular Dystrophy | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04371666) |
| September 4, 2019 | NCT04076943 | Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia | Kyntra Bio | Phase 2 | Completed | Chemotherapy Induced Anemia | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04076943) |
| August 16, 2019 | NCT04059913 | Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic... | Kyntra Bio | Phase 4 | Completed | CKD Anemia in Dialysis Participants | 318 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04059913) |
| May 17, 2019 | NCT03955146 | Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Kyntra Bio | Phase 3 | Terminated | Idiopathic Pulmonary Fibrosis | 393 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03955146) |
| May 7, 2019 | NCT03941093 | Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus... | Kyntra Bio | Phase 3 | Completed | Pancreatic Cancer Non-resectable | 284 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03941093) |
| October 5, 2017 | NCT03303066 | Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS) | Kyntra Bio | Phase 2/3 | Completed | Anemia, Myelodysplastic Syndrome | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03303066) |
| August 28, 2017 | NCT03263091 | Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell... | Kyntra Bio | Phase 3 | Terminated | Primary MDS (Very Low, Low or Intermediate IPSS-R With \<5% Blasts), Anemia | 184 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03263091) |
| January 12, 2016 | NCT02652819 | FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis | Kyntra Bio | Phase 3 | Completed | Anemia | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02652819) |
| January 12, 2016 | NCT02652806 | FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease | Kyntra Bio | Phase 3 | Completed | Anemia | 305 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02652806) |
| November 17, 2015 | NCT02606136 | Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | Kyntra Bio | Phase 2 | Terminated | Duchenne Muscular Dystrophy | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02606136) |
| October 24, 2014 | NCT02273726 | Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis | Kyntra Bio | Phase 3 | Completed | CKD Anemia in Stable Dialysis Patients | 741 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02273726) |
| August 6, 2014 | NCT02210559 | A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer | Kyntra Bio | Phase 1/2 | Completed | Pancreatic Cancer (Unresectable) | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02210559) |
| February 3, 2014 | NCT02052310 | Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis... | Kyntra Bio | Phase 3 | Completed | Anemia in Incident Dialysis Patients | 1,043 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02052310) |
| July 1, 2013 | NCT01890265 | Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Kyntra Bio | Phase 2 | Completed | Idiopathic Pulmonary Fibrosis | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01890265) |
| December 17, 2012 | NCT01750190 | A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis | Kyntra Bio | Phase 3 | Completed | CKD Anemia | 922 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01750190) |
| June 28, 2012 | NCT01630889 | Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic... | Kyntra Bio | Phase 2 | Completed | Chronic Kidney Disease, End Stage Renal Disease, Anemia | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01630889) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 6 |
| Phase 1/2 | 1 |
| Phase 2 | 16 |
| Phase 2/3 | 1 |
| Phase 3 | 16 |
| Phase 4 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 28 |
| Terminated | 10 |
| Withdrawn | 1 |
| Not yet recruiting | 1 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Anemia | 18 |
| Renal Insufficiency, Chronic | 10 |
| Kidney Failure, Chronic | 7 |
| Idiopathic Pulmonary Fibrosis | 5 |
| Pulmonary Fibrosis | 4 |
| Muscular Dystrophy, Duchenne | 3 |
| Diabetes Mellitus, Type 2 | 3 |
| Myelodysplastic Syndromes | 3 |
| Idiopathic Interstitial Pneumonias | 3 |
| Lung Diseases, Interstitial | 3 |
| Pancreatic Neoplasms | 2 |
| Diabetes Mellitus | 2 |
| Diabetic Nephropathies | 2 |
| Muscular Dystrophies | 1 |
| Muscular Disorders, Atrophic | 1 |
| Muscular Diseases | 1 |
| Musculoskeletal Diseases | 1 |
| Neuromuscular Diseases | 1 |
| Nervous System Diseases | 1 |
| Genetic Diseases, Inborn | 1 |
| Genetic Diseases, X-Linked | 1 |
| Respiration Disorders | 1 |
| Proteinuria | 1 |
| Glomerulosclerosis, Focal Segmental | 1 |
| Renal Insufficiency | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Billing services in the United States](https://specstream.ai/data/businesses/billing-services/united-states)
- [Periodontics practices in the United States](https://specstream.ai/data/businesses/periodontics-practices/united-states)
- [Demolition contractors in the United States](https://specstream.ai/data/businesses/demolition-contractors/united-states)
- [Sleep medicine clinics in the United States](https://specstream.ai/data/businesses/sleep-medicine-clinics/united-states)
- [Freight forwarders in the United States](https://specstream.ai/data/businesses/freight-forwarders/united-states)
- [Waterproofing contractors in the United States](https://specstream.ai/data/businesses/waterproofing-contractors/united-states)
